Gallagher Tyler J, Chung Ryan S, Lin Matthew E, Kim Ian, Kokot Niels C
Keck School of Medicine of the University of Southern California, Los Angeles.
Department of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles.
JAMA Otolaryngol Head Neck Surg. 2024 Dec 1;150(12):1068-1075. doi: 10.1001/jamaoto.2024.2419.
Cannabis is the most commonly used illicit substance worldwide. Whether cannabis use is associated with head and neck cancer (HNC) is unclear.
To assess the clinical association between cannabis use and HNC.
DESIGN, SETTING, AND PARTICIPANTS: This large multicenter cohort study used clinical records from a database that included 20 years of data (through April 2024) from 64 health care organizations. A database was searched for medical records for US adults with and without cannabis-related disorder who had recorded outpatient hospital clinic visits and no prior history of HNC. Propensity score matching was performed for demographic characteristics, alcohol-related disorders, and tobacco use. Subsequently, relative risks (RRs) were calculated to explore risk of HNC, including HNC subsites. This analysis was repeated among those younger than 60 years and 60 years or older.
Cannabis-related disorder.
Diagnosis of HNC and any HNC subsite.
The cannabis-related disorder cohort included 116 076 individuals (51 646 women [44.5%]) with a mean (SD) age of 46.4 (16.8) years. The non-cannabis-related disorder cohort included 3 985 286 individuals (2 173 684 women [54.5%]) with a mean (SD) age of 60.8 (20.6) years. The rate of new HNC diagnosis in all sites was higher in the cannabis-related disorder cohort. After matching (n = 115 865 per group), patients with cannabis-related disorder had a higher risk of any HNC (RR, 3.49; 95% CI, 2.78-4.39) than those without HNC. A site-specific analysis yielded that those with cannabis-related disorder had a higher risk of oral (RR, 2.51; 95% CI, 1.81-3.47), oropharyngeal (RR, 4.90; 95% CI, 2.99-8.02), and laryngeal (RR, 8.39; 95% CI, 4.72-14.90) cancer. Results were consistent when stratifying by older and younger age group.
This cohort study highlights an association between cannabis-related disorder and the development of HNC in adult patients. Given the limitations of the database, future research should examine the mechanism of this association and analyze dose response with strong controls to further support evidence of cannabis use as a risk factor for HNCs.
大麻是全球最常用的非法物质。大麻使用是否与头颈癌(HNC)相关尚不清楚。
评估大麻使用与HNC之间的临床关联。
设计、背景和参与者:这项大型多中心队列研究使用了一个数据库中的临床记录,该数据库包含64个医疗机构20年的数据(截至2024年4月)。在数据库中搜索有和没有大麻相关疾病的美国成年人的医疗记录,这些人有门诊医院就诊记录且无HNC既往史。对人口统计学特征、酒精相关疾病和烟草使用进行倾向评分匹配。随后,计算相对风险(RRs)以探索HNC的风险,包括HNC亚部位。在60岁以下和60岁及以上人群中重复此分析。
大麻相关疾病。
HNC及任何HNC亚部位的诊断。
大麻相关疾病队列包括116076人(51646名女性[44.5%]),平均(标准差)年龄为46.4(16.8)岁。非大麻相关疾病队列包括3985286人(2173684名女性[54.5%]),平均(标准差)年龄为60.8(20.6)岁。大麻相关疾病队列中所有部位新诊断的HNC发生率更高。匹配后(每组n = 115865),患有大麻相关疾病的患者发生任何HNC的风险(RR,3.49;95%CI,2.78 - 4.39)高于未患HNC的患者。特定部位分析显示,患有大麻相关疾病的患者患口腔癌(RR,2.51;95%CI,1.81 - 3.47)、口咽癌(RR,4.90;95%CI,2.99 - 8.02)和喉癌(RR,8.39;95%CI,4.72 - 14.90)的风险更高。按年龄组分层时结果一致。
这项队列研究突出了大麻相关疾病与成年患者HNC发生之间的关联。鉴于数据库的局限性,未来研究应探讨这种关联的机制,并在严格控制下分析剂量反应,以进一步支持大麻使用作为HNC风险因素的证据。